Literature DB >> 6948570

Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes.

M Cazzola, G Barosi, C Berzuini, M Dacco, E Orlandi, M Stefanelli, E Ascari.   

Abstract

Based on the morphological appearances of the bone marrow and peripheral blood, 43 patients with dysmyelopoietic syndromes were categorized into four types: refractory anaemia with excess of blasts, chronic myelomonocytic leukaemia, primary acquired sideroblastic anaemia and refractory anaemia with cellular marrow, without excess of blasts and/or ring sideroblasts. Ferrokinetics allowed three distinct groups of patients to be defined. All cases of refractory anaemia with excess of blasts and chronic myelomonocytic leukaemia were classified in the same group. They were characterized by relative marrow failure and had a high likelihood of developing acute leukaemia. At the other end of the spectrum, individuals with primary acquired sideroblastic anaemia had high erythropoietic activity which was largely ineffective. They had a benign clinical course without evidence of leukaemic transformation. In the middle group, in terms of erythropoietic activity, lay patients with refractory anaemia with cellular marrow and a few individuals with primary acquired sideroblastic anaemia. Their clinical course and risk of developing acute leukaemia were intermediate between the other two groups. These findings indicate that separate entities may exist within the spectrum of dysmyelopoietic syndromes. In clinical practice, they may be recognized by morphological studies and other simple laboratory means.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6948570     DOI: 10.1111/j.1365-2141.1982.tb01890.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  Erythrocyte autoantibodies, autoimmune haemolysis, and myelodysplastic syndromes.

Authors:  R J Sokol; S Hewitt; D J Booker
Journal:  J Clin Pathol       Date:  1989-10       Impact factor: 3.411

2.  Refractory anaemia terminating in a combined lymphoproliferative and myeloproliferative disorder.

Authors:  L Camba; M V Joyner
Journal:  J Clin Pathol       Date:  1985-03       Impact factor: 3.411

3.  Ring sideroblasts and myelodysplastic syndromes.

Authors:  M Cazzola
Journal:  J Clin Pathol       Date:  1983-12       Impact factor: 3.411

Review 4.  Management of anemia in low-risk myelodysplastic syndromes treated with erythropoiesis-stimulating agents newer and older agents.

Authors:  Roberto Castelli; Riccardo Schiavon; Valentina Rossi; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2018-04-19       Impact factor: 3.064

5.  Comparative ferrokinetic study with initial and extended iron clearance models.

Authors:  J E Howarth; H M Waters; K Hyde; D Shanks; C G Geary
Journal:  J Clin Pathol       Date:  1991-05       Impact factor: 3.411

6.  Prevalence and distribution of ringed sideroblasts in primary myelodysplastic syndromes.

Authors:  S K Juneja; M Imbert; F Sigaux; H Jouault; C Sultan
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

Review 7.  Hematopoietic growth factors and the treatment of tumor-associated anemias.

Authors:  U Dührsen; D K Hossfeld
Journal:  Ann Hematol       Date:  1994-11       Impact factor: 3.673

8.  Pseudoreticulocytosis in a patient with myelodysplasia.

Authors:  B Hertenstein; E Kurrle; M Redenbacher; R Arnold; H Heimpel
Journal:  Ann Hematol       Date:  1993-09       Impact factor: 3.673

Review 9.  Myelodysplastic syndromes: pathogenesis, functional abnormalities, and clinical implications.

Authors:  A Jacobs
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

10.  Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1.

Authors:  Ilaria Ambaglio; Luca Malcovati; Elli Papaemmanuil; Coby M Laarakkers; Matteo G Della Porta; Anna Gallì; Matteo C Da Vià; Elisa Bono; Marta Ubezio; Erica Travaglino; Riccardo Albertini; Peter J Campbell; Dorine W Swinkels; Mario Cazzola
Journal:  Haematologica       Date:  2013-01-08       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.